Neurochemical characteristics of the effects of delta sleep-inducing peptide in Wistar rats with hyperactivity of the dopaminergic system.
Sergutina. A V AV; Gershtein. L M LM
Key Findings
- DSIP raised monoamine oxidase activity (serotonin/tryptamine breakdown) in the caudate and accumbens nuclei.
- DSIP increased glutamate dehydrogenase activity in the hippocampus.
- No changes were seen in sensorimotor cortex enzyme activity, acetylcholinesterase, or aminopeptidase levels.
Practical Outcomes
- The findings are mostly of scientific interest and don’t translate into a clear, usable protocol for humans. While DSIP appears to affect neurotransmitter‑metabolizing enzymes in specific brain regions of rats, there’s no evidence it improves sleep, mood, or performance in people, nor guidance on dosing or safety.
Summary
In a rat study, a single dose of delta sleep‑inducing peptide (DSIP) boosted the activity of enzymes that break down serotonin and other monoamines in parts of the brain linked to reward, and increased an enzyme involved in glutamate metabolism in the hippocampus. It didn’t change enzyme activity in the sensorimotor cortex or affect enzymes that handle acetylcholine.
Abstract
Quantitative cytochemical assay showed that single injection of delta sleep-inducing peptide increased monoamine oxidase activity (substrates: serotonin and tryptamine) in the caudate and accumbens nuclei and glutamate dehydrogenase activity in the hippocampus of stress-resistant Wistar rats chronically treated with L-DOPA. Enzyme activities in the sensorimotor cortex did not change. Delta sleep-inducing peptide had no effects on acetylcholine esterase and aminopeptidase activities in the brain of Wistar rats.
Study Information
pubmed
2000